Last reviewed · How we verify

Tyvaso®

Insmed Incorporated · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

Tyvaso® is a Small molecule drug developed by Insmed Incorporated. It is currently FDA-approved. Also known as: Inhaled treprostinil.

Tyvaso is a small molecule drug that acts as a prostanoid IP receptor agonist. It is used to treat conditions such as Pulmonary Arterial Hypertension, and is administered via subcutaneous injection.

At a glance

Generic nameTyvaso®
Also known asInhaled treprostinil
SponsorInsmed Incorporated
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Tyvaso®

What is Tyvaso®?

Tyvaso® is a Small molecule drug developed by Insmed Incorporated.

Who makes Tyvaso®?

Tyvaso® is developed and marketed by Insmed Incorporated (see full Insmed Incorporated pipeline at /company/insmed-incorporated).

Is Tyvaso® also known as anything else?

Tyvaso® is also known as Inhaled treprostinil.

What development phase is Tyvaso® in?

Tyvaso® is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing